Shanghai Kehua Bio-engineering (002022.SZ): The hepatitis C virus (HCV) nucleic acid detection kit (PCR-fluorescence method) has obtained a medical device registration certificate.
Kehua Bio (002022.SZ) announced that its subsidiary, Suzhou Tianlong Biotechnology Co., Ltd., has recently...
Shanghai Kehua Bio-engineering (002022.SZ) announced that its holding subsidiary, Suzhou Tianlong Bio-technology Co., Ltd., has received a medical device registration certificate (in vitro diagnostic reagent) issued by the National Medical Products Administration. The product involved is the "Hepatitis C Virus (HCV) Nucleic Acid Detection Kit (PCR-fluorescence method)". This product is used for quantitatively detecting Hepatitis C Virus nucleic acid (RNA) in human serum or plasma samples.
Related Articles
ZHIHUI MINING (02546) plans to acquire a 60% stake in Tibet Dachuan Mining.
SHUN TAK HOLD (00242) announces annual performance: Shareholders' net loss of HK$478 million, a year-on-year decrease of 41.96%
GUANGDONG INV(00270)Subsidiary plans to sell 35% equity of Guangdong AEON STORES.
ZHIHUI MINING (02546) plans to acquire a 60% stake in Tibet Dachuan Mining.
SHUN TAK HOLD (00242) announces annual performance: Shareholders' net loss of HK$478 million, a year-on-year decrease of 41.96%
GUANGDONG INV(00270)Subsidiary plans to sell 35% equity of Guangdong AEON STORES.
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026
